Seres Therapeutics, Inc. (NASDAQ:MCRB) Insider Sells $26,438.40 in Stock

Seres Therapeutics, Inc. (NASDAQ:MCRB) insider Teresa L. Young sold 24,480 shares of the stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $1.08, for a total transaction of $26,438.40. Following the transaction, the insider now directly owns 78,178 shares of the company’s stock, valued at $84,432.24. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Seres Therapeutics Trading Down 21.1 %

NASDAQ:MCRB traded down $0.27 during mid-day trading on Tuesday, reaching $1.01. 14,446,355 shares of the stock were exchanged, compared to its average volume of 4,714,470. Seres Therapeutics, Inc. has a 1-year low of $0.54 and a 1-year high of $5.22. The firm has a market capitalization of $152.96 million, a PE ratio of -1.73 and a beta of 1.97. The business has a fifty day moving average price of $0.97 and a 200 day moving average price of $0.95.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.09. On average, sell-side analysts forecast that Seres Therapeutics, Inc. will post -1.03 earnings per share for the current year.

Analyst Ratings Changes

Several research analysts recently issued reports on MCRB shares. Oppenheimer restated a “market perform” rating on shares of Seres Therapeutics in a research report on Friday, June 7th. Chardan Capital dropped their target price on Seres Therapeutics from $8.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, May 8th. Canaccord Genuity Group dropped their price target on Seres Therapeutics from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, June 7th. Finally, StockNews.com raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, July 9th.

Institutional Trading of Seres Therapeutics

Hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. bought a new position in Seres Therapeutics during the first quarter worth about $39,000. Tower Research Capital LLC TRC grew its holdings in Seres Therapeutics by 668.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 38,091 shares of the biotechnology company’s stock worth $53,000 after acquiring an additional 33,135 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of Seres Therapeutics during the first quarter valued at approximately $73,000. SG Americas Securities LLC acquired a new stake in shares of Seres Therapeutics in the fourth quarter valued at approximately $73,000. Finally, Pennant Investors LP acquired a new position in Seres Therapeutics during the 4th quarter worth $409,000. 59.34% of the stock is owned by institutional investors.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.